PubMed Health⌕ Search

Biomedical subjects

V P Kuznetsov

Publications and source records attributed to V P Kuznetsov.

At least 127 records · Page 7Linked to original sources
PubMedDate not supplied

[Antiproliferative activity of different preparations of human interferons].

The conclusion that the AP activity of IFN in the ChLI-1 preparation was not lost but masked by an admixture of obscure factors was drawn on the basis of coefficients of AV/AP ratio titres of IFN-alpha preparations of various degrees of purification prepared at the Gamaleia Institute of Epidemiology and Microbiology and the shape of curves of the AP effect. It was found that the curve of AP activity of diluted interferon may be of parabolic shape which reflected AP effect of high and low concentrations in the absence of AP effect for some intermediate dilutions. This is due to competitive relationships of the growth-stimulating factors and IFN upon non-simultaneous elimination of its individual subtypes. The existence of a curve of such shape indicates the expediency of testing lower concentrations than those which are characterized by a sigmoid shape of curves of AP activity, especially for cells with low sensitivity to interferon.

Cell Division↗
PubMedDate not supplied

[The pharmacokinetics of recombinant alpha 2-interferon (reaferon)].

The use of electrochemical iodination under potentiostatic conditions resulted in generating 131I-labeled alpha 2-interferon (IF) the antiviral activity of which differed statistically insignificantly from that of the intact preparation. The resulting radioactive analogue of alpha 2-IF was successfully used for the study of pharmacokinetics of reaferon (RFN) in experimental animals which determined the parameters of the processes of its elimination from the blood stream, accumulation and release from the liver, the organ in which the highest accumulation of alpha 2-IF is observed. It is concluded from the foregoing that it would be expedient to use RFN for treatment of viral disease of the liver and the lungs.

Animals↗
PubMedDate not supplied

[Activation of gamma-interferonogenesis].

Production of gamma-interferon was increased considerably by priming with homologous gamma- or alpha-interferons as well as by T-activin or vitamins of group B. The factors under study were effective both in the population of mononuclears and in the total fraction of nucleated cells of the donor blood. The maximal yields of gamma-interferon, up to 10,000 IU/ml, could be obtained by priming with gamma-interferon in a dose of 5 IU/ml or alpha-interferon in a dose of 1000 IU/ml. T-activin and vitamin B12 also enhanced production 8-10-fold. The combined use of priming, T-activin, and vitamin B12 in various combinations gave no further increase in the yield of activity.

Cells, Cultured↗
PubMedDate not supplied

[Indices of alpha-interferon and of lymphocyte natural killer activity in genital herpes and the effect on them of specific vaccinal therapy and interferon therapy].

Fifty-six patients with recurrent genital herpes (RGH) and 53 normal subjects were examined. No interferon was found in the blood sera of the patients either in the period of the disease relapse or during remission. The leukocyte capacity to produce interferon in vitro (leukocyte interferon reaction, LIR) in the patients was found to be 4-5 times lower than in normal subjects. Study of the normal killer activity of lymphocytes in patients with RGH as compared with that in normal subjects revealed its decrease in 37.5% of the patients and only in 5.1% of normal subjects. Interferon therapy with purified human leukocyte interferon given to 36 patients with RGH resulted in clinical improvement in 88.9% of the patients that was accompanied by increasing normal killer activity of lymphocytes. Vaccine therapy given to 35 patients resulted in a stable clinical effect in 91.4% of the patients, however, without activation of LIR in them. It is concluded that the therapeutic effects of interferon therapy and vaccine therapy have different mechanisms.

Adult↗
PubMedDate not supplied

[Patterns in the biosynthesis and action of human gamma-interferon].

The highest yields of gamma-interferon activity were obtained by using a fraction of mononuclears recovered from freshly collected donor blood in ficoll-verografin density gradient without using hemolysis. Unification of mononuclears from individual donors into a common pool stimulated interferon production. Staphylococcal enterotoxins A and B, concanavalin A, and lentyl-lectin were found to be the most effective inducers. Immobilization of inducers on neutral carriers reduced their effectiveness. Upon induction with lectin the synthesis was complete within 24 hours, and with enterotoxin in 3 days. In the latter instance the synthesis dynamics was of a two-phase nature. Gamma-interferon produced the antiviral condition later (in 10 hours) than alpha-interferon.

Cells, Cultured↗
PubMedDate not supplied

[A macrophage migration-inhibiting factor in preparations of alpha- and gamma-interferon].

Native preparations of human alpha- and gamma-interferon synthesized in stationary, suspension or roller leukocyte cultures regularly showed high levels of migration inhibition factor (MIF) activity a significant portion of which was lost in the course of interferon purification and concentration. Minimal losses of MIF activity were achieved when medicinal preparations of interferon were made by the method of negative immunoabsorption on immobilized antibodies to inductor antigens and chromatography on Sephadex G-25.

Animals↗
PubMedDate not supplied

[Leukocyte migration inhibiting factor in preparations of alpha and gamma interferons].

High titres of leukocyte migration inhibition factor (LMIF) activity were found in native and partially purified preparations of human alpha- and gamma-interferon. In the course of chemical purification of interferon up to 98% of LMIF was lost. The highest content of LMIF was in gamma-interferon preparations, while recombinant alpha 2-interferon (reaferon) showed no LMIF activity.

Cell Migration Inhibition↗
PubMedDate not supplied

[Activation of phagocytosis by preparations of human alpha and gamma interferons].

Preparations of human alpha- and gamma-interferon differing by the method of production and purification had different capacity of activating phagocytosis of blood polymorphonuclear leukocytes from patients with dermatoses. Native preparations of alpha- and gamma-interferon had the highest phagocytosis-activating potency. A high level of this activity was also demonstrated with human leukocyte interferon II for injections purified by highly specific methods. A concentrated preparation of human leukocyte interferon for injections with a specific activity above 1 million IU/1 mg of protein and recombinant alpha 2-interferon (reaferon) exhibited minimal phagocytosis activating effect.

Cells, Cultured↗
PubMedDate not supplied

[Smallpox vaccination with protection by interferon and an interferon inducer].

The vaccinal process was studied in monkeys vaccinated with smallpox vaccine under the protection of fibroblastic or leukocytic interferons and modified poly(I) . poly(C). Simultaneous vaccination and administration of one of the studied preparations induced intense immunity and at the same time prevented viremia and alleviated local inflammatory reactions caused by the vaccination. The protective effect of the fibroblastic interferon was more marked than that of the leukocytic one in the vaccinal process. When the monkeys received the preparations intramuscularly the leukocytic but not the fibroblastic interferon was detected in the blood.

Animals↗
PubMedDate not supplied

[Method of increasing the activity of a preparation of human cadaver leukocyte interferon].

A simple method for increasing the activity of human leukocyte interferon is described. It is based on the removal from the native preparation of a presumed inhibitor of antiviral effect followed by condensation of the resulting fractions by thin-canal cells TCF-10 of an Amicon apparatus. With this method of concentration there was no loss of the general initial antiviral activity. Depending on the titer of the initial interferon and the condensation degree, the native interferon was concentrated 32--350-fold. The resulting concentrated interferon preparation is nontoxic, areactogenic, safe in animal trials and may be recommended for trials as a therapeutic-prophylactic means in various viral diseases.

Animals↗
PubMedDate not supplied

[Distribution of human interferon in organs and tissues after its administration to man and animals].

After intramuscular inoculation of interferon to mice and rabbits it accumulated in serum (6 hours after inoculation) and some organs (16 hours) and subsequently disappeared. Intravenous inoculation produced an earlier appearance (within 6 hours) of interferon in organs and more rapid disappearance. Neither intramuscular nor intravenous inoculation resulted in interferon penetration into the bone marrow. A similar picture was observed in children with acute leukemia after intramuscular inoculation of interferon. Inoculation of interferon into bones of the children resulted in its deposition for a few days in the bone marrow with subsequent transition into the blood stream.

Animals↗
PubMedDate not supplied

[Optimal conditions for demonstrating the antimitotic action of interferon].

The effect of human leukocyte interferon (HLI) on three human cell cultures of different origin was studied. HLI inhibited the mitotic activity (MA) of human ovary carcinoma cell culture and to a lower extent that of a diploid cell culture. At the same time HLI preparation exerted a nonspecific stimulating effect on MA of the primary human embryo cell culture. The optimal conditions for the determination of the antimitotic effect of interferon on cells of tumor origin include: a seed dose of 5 X 10(4) cells/ml, addition of interferon to the culture 24 hours after cell seeding; the maximum effect of interferon is observed at 24 hours after addition to the culture.

Carcinoma↗